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vessels to a level comparable to uninjured vessels. The NOS- 
3-transfected vessels showed a -70% reduction in neointimal 
thickness as compared with control injured carotid arteries. These 
results uggest NOS gene transfer may be beneficial in restenosis. 
A very important consideration that must be weighed is gene 
delivery efficiency by viral or nonviral methods. For clinical 
applications, vascular gene transfer must be accomplished with a 
minimal period of flow occlusion, especially in the coronary 
circulation, where minutes of occlusion can result in significant 
myocardial ischemia or infarction. With even the most efficient 
delivery system, that being the adenoviral vector, gene transfer 
efficiency will be low. For this reason, we hypothesize that gene 
delivery of the NOS-2 isoform may have some advantages over 
NOS-3. Low-efficiency transfer of this extremely active enzyme 
may still provide sufficient local concentrations of NO to achieve a
biologic effect. In addition, NOS-2 activity does not require 
calcium fluxes and will be maximal in the absence of agonist 
stimulation. 
Cytotoxicity from NOS-2 overexpression in native cells is a 
potential concern. Also, all NOS enzymes require the cofactor 
tetrahydrobiopterin (BH4). Certain cells lack constitutive biosyn- 
thesis of this cofactor and may be unable to support NOS-2 
activity, sBecause of these concerns, we evaluated the feasibility of 
NOS-2 gene transfer to vascular target cells. We constructed a 
retroviral vector carrying the human NOS-2 cDNA and neomycin 
phosphotransferase (DFGiNOS). 9 Sheep vascular endothelial cells 
infected with DFGiNOS and selected with neomycin supported 
mammal NOS-2 activity, producing over 20-fold more nitrite 
(NO2-) than cells infected with a control retrovirus ( 155.0 + 10.7 
nmol /mg protein/24 hr vs 5.5 _+ 1.1), without requirements for 
supplemental BH4. In contrast, rat vascular smooth muscle cells 
infected with DFGiNOS had no detectable NO 2- accumulation 
over control cells until BH 4 was provided (37.7 + 2.6 nmol /mg 
protein/24 hrwithout BH4,291.8 +_ 10.4withBH4),demonstrat- 
ing the insufficient cofactor levels in these cells. Interestingly, 
continuous expression of NOS-2 with NO synthesis did not result 
in significantly increased cytotoxicity as measured by Slchromium 
or lactate dehydrogenase release. 
We adapted an ex vivo organ culture system of arterial injury l° 
to assess the biologic efficacy of human NOS-2 gene transfer for 
preventing myointimal hyperplasia. Porcine femoral arterial seg- 
ments were infected with the DFGiNOS retrovirus or a control 
retrovirus 5 days after balloon-catheter injury and then cultured 
for another 9 days. By the fifth day after surgery, near maximal 
smooth muscle proliferation is occurring, 1° a favorable nviron- 
ment for retroviral infection. Vessels infected with DFGiNOS 
demonstrated a threefold increase in NO synthesis and a 15-fold 
increase in cGMP release over uninjured or control manipulated 
vessels. All early experiment had revealed a dependence ofNOS-2 
activity in these arterial segments on exogenous BH4, which was 
subsequently provided to all the experimental groups. Immuno- 
histochemical nalysis revealed only a 1% to 2% gene transfer 
efficiency, as would be expected with a retroviral vector. Balloon 
injury of the arterial segments resulted in a 53% increase in total 
myointimal thickness. Vessels expressing NOS-2, however, had a 
complete abrogation of this hyperplastic response and resembled 
uninjured controls; the administration fa NOS inhibitor eversed 
this protective ffect. 
Despite very low gene transfer efficiency, NOS 2 delivery to 
injured arterial segments successfully reduced intimal hyperplasia. 
The requirement for BH 4 is consistent with preferential delivery of 
the NOS-2 gene to the smooth muscle cells. Ongoing studies are 
aimed at determining whether the cofactor will be required for 
NOS-2 gene transfer in vivo and whether NOS-2 transfer will be of 
benefit in models of restenosis n large animals. 
Timothy R. Billiar, MD 
Edith Tzeng, MD 
Larry L. Shears II, MD 
University of Httsburgh Medical Center 
Pittsburgh, Pa. 
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D IRECT TRANSFER- -  
V IRAL  APPROACHES 
ADENOVIRAL VECTORS: PROMISES 
AND P ITFALLS  
Human adenovirus, representing over 40 different serotypes, are 
36 kb double-stranded DNA viruses. The molecular structure and 
regulation of this virus has been well studied over the years. The 
virus was first used in the 1980's for introducing foreign genes into 
cells. More recently, the E1 region of the virus that expresses 
transcriptional f ctors necessary to induce appropriate synthesis of 
the more than 70 viral proteins needed for viral replication has been 
removed, supplied in trans, and replaced with therapeutic gene 
sequences. Over the past 5 years, multiple studies performed by 
different laboratories have demonstrated that recombinant ade- 
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novirus vectors hold promise for use in gene transfer into a number 
of different issues as a means of performing ene therapy for 
genetic and acquired disorders. The advantages in using these 
vectors are the result of: (1) the wide variety of cell types that can 
be transduced invitro and in vivo; (2) the ability to ~oncentrate the 
vector to high titers of up to 10 I2 pfu/ml; (3) the fact that gene 
transfer occurs without he requirement ofcellular division and the 
viral genome does not integrate into the host chromosome. The 
distribution of vector DNA in tissues is dependent on the route of 
administration. Most of the virus is taken up by hcpatocytes when 
given by peripheral or portal vein infusion. In fact, in multiple 
animal models, 100% ofhepatocytes can be transduced with up to 
50 genome copies per cell. The vector can be delivered to the lungs, 
muscle, endothelial cells, and the central nervous system with 
relatively high efficiency. 
The excitement of using these vectors for gene therapy was 
tempered by a relatively short term of gene expression and the 
inability to transduce cells a second time in animal models. 
Interestingly, although the vector DNA does not integrate into the 
cell, vectors administered to mice deficient in antigen-dependent 
immunity have long-term persistence of over 10 months in some 
studies. Additionally, functional B and T cell deficiency allows for 
repeated transduction. 
Data from several groups using murine models ofgene therapy 
directed towards the lung and the liver have helped to elucidate thc 
nature of the immune responses limiting adenoviral-mediated g ne 
therapy. In sum, it appears that T cell-dependent, antigen-specific 
immunity limits the duration of transduced gene expression after 
inoculation of native animals, and largely prevents gene expression 
after secondary administration. Using mice with selective absence 
of CD8 or CD4 T ceils or B cells, it appears that (1) CD8 T cells 
play a predominant role in limiting the duration of gene expres- 
sion by eliminating transduced ceils or the transduced gene 
product, whereas CD4 T cells play a contributory role; and (2) 
CD4 T cells, by providing help to B cells, facilitate the production 
of neutralizing antibody in the serum and the airways, which 
precludes gene expression after secondary administration of the 
same or related adenoviral vectors. Based on a number of different 
studies, it appears that the CD8-mediated immune response is 
largely directed to newly synthesized viral gene products that are 
produced at low levels in the cells of the animals receiving the 
first generation viruses. 
There are two major approaches that will be needed to 
combat he immunologic response to the vector. The first is to 
produce a less antigenic vector. Advanced generation adenovirus 
vectors deleted for specific portions of the viral genome have been 
produced in different laboratories and are currently being tested 
in a variety of animal models. To date, some of these vectors 
include second-generation adenoviral vectors with E2 mutations, 
deletions, or deletions in the E4 region. Although the preliminary 
studies are not conclusive, they suggest that although these 
vectors may offer an improvement over the first-generation vec- 
tors as far as persistence of gene expression is concerned, the 
immune response will most likely limit the natural lifetime of 
vector DNA in host target tissues. Technical advances hould 
eventually lead to the production of a vector deleted of all viral 
genes. Although these types of vectors hould allow for maximal 
persistence of vector in transduced cells, the antibody response is
largely directed against virion proteins present in the vector coat; 
thus, even in the absence of viral protein synthesis, a humoral 
immune response will more than likely remain. Attenuation of the 
immune response would facilitate more prolonged gene expres- 
sion and minimize inflammation after initial vector administration 
and will most certainly be necessary if secondary gene transduc- 
tion is to be achieved. 
Immunomodulatory regimens used as adjunct herapy may be 
necessary to achieve long-term or repeat gene transfer. Conven- 
tional immunosuppressive agents, such as cyclosporin, have not 
proven effective in mitigating immune-mediated clearance of 
expression. Rather, some success has been achieved using cytoab- 
lative therapy. However, this approach results in untoward effects 
and is broadly immunosuppressive. In order to enhance gene 
expression, we have sought and obtained partial success in modi- 
fying the host response by selectively blocking the interactions of 
costimulatory ligands on T lymphocytes and antigen presenting 
ceils (APC), which play an important role in the initiation of an 
effective, antigen-specific immunologic response. Blockade of the 
costimulatory interactions between CD28 on T cells with B7 -1,-2 
on A,PC using soluble CTLA4Ig is one such example. Mice given 
soluble CTLA4Ig near the time of hepatic gene transfer with a 
first-generation recombinant adenovirus had persistent gene ex- 
pression for 6 months (length of experiment), whereas control 
animals had a fall-off of  gene expression within the first 2 to 
7 weeks. The mechanism by which CTLA4Ig prolonged adeno- 
virus-mediated gene expression was investigated by studying the 
T cell responses of recipients. Proliferation of splenic T cells in 
response to the adenovirus was evident in control animals that 
received the vector as early as day 11, but was absent or markedly 
reduced in animals that received CTLA4Ig. In agreement with the 
in vitro splenocyte assays, T cell infiltration into the livers of 
muCTLA4Ig treated mice was minimal and similar to that seen 
in mice not receMng adenovirus, whereas control mice that 
received adenovirus had robust infiltration of CD3, CD4, and 
CD8 positive cells. CTLA4Ig therapy resulted in a marked and 
significant reduction ofneutrafizing antibodies but did not totally 
ablate the response. Ongoing studies using other costimulatory 
blocking agents in combination with CTLA4Ig are in progress 
and demonstrate he ability to block humoral immunity as well 
in about 50% of treated mice. 
This type of therapy has several potential advantages over 
cytoablative therapy: (1) it results in transient immunosuppression; 
(2) it is not cytoablative and does not affect other ceils (e.g., 
neutrophils) involved in innate immune responses; (3) it has 
minimal effect on preexisting immunity; and (4) it is unlikely to 
result in immunologic tolerance to wild-type adenovirus. 
The theoretic ability to use recombinant adenovirus vectors as 
an efficient means of successfully performing gene transfer in 
human beings has been hampered by the resulting immunologic 
response against he vector. Although modifications of the vector 
are simple in concept, they are plagued with technical difficulties 
that have just begun to be overcome. Thus with the improvements 
in the vector and the possibility of using adjunct immunomodula- 
tion regimens, the next few years will be important for determining 
the suitability of these vectors for gene therapy relating to disorders 
requiring shorvterm, long-term, or repeat gene transfer for clinical 
gene therapy. 
Mark Kay, MD, PhD 
University of Washington 
Seattle, Wash. 
MODIF ICAT ION OF  VE IN  GRAFT 
ADAPTAT ION US ING ADENOVIRAL  VECTORS 
The devastating severity and epidemic proportions of arterial 
occlusive disease have made arterial bypass procedures among the 
most frequently performed operations. Ten years ago, 70,000 
